CG Oncology, a pioneering biopharmaceutical company, has embarked on a transformative journey in the realm of cancer therapeutics with the initiation of the Phase III PIVOT-006 clinical trial for cretostimogene. This milestone endeavour marks a significant leap forward in addressing the pressing medical needs of patients grappling with intermediate-risk non-muscle invasive bladder cancer (NMIBC). With the dosing of the first subject, the trial sets forth a promising trajectory towards enhancing treatment options and improving outcomes for individuals facing recurrent tumours and limited therapeutic avenues.
The PIVOT-006 trial, designed as an open-label, two-arm, monotherapy study, aims to enrol 426 NMIBC patient’s post-transurethral resection of the bladder tumour (TURBT). This meticulous patient selection process underscores the trial’s commitment to evaluating the efficacy and safety profile of cretostimogene in a targeted population. By focusing on patients at intermediate risk, the trial addresses a critical gap in the current treatment landscape, where therapeutic options are often limited, and disease recurrence poses a persistent challenge.
The strategic dosing regimen employed in the trial underscores a multifaceted approach to maximizing therapeutic benefit and enhancing patient outcomes. The induction course comprises six weekly doses of adjuvant cretostimogene, followed by maintenance courses for patients exhibiting no signs of recurrence at the three-month mark. This comprehensive treatment strategy not only emphasizes the importance of early intervention but also aims to prolong recurrence-free survival (RFS) and progression-free survival. With RFS serving as the trial’s primary endpoint and additional secondary endpoints, including RFS at 12 and 24 months, the trial sets a robust framework for assessing cretostimogene’s therapeutic potential comprehensively.
Arthur Kuan, chairman and CEO of CG Oncology, articulates the urgency of addressing the complex challenges faced by intermediate-risk NMIBC patients. By advancing cretostimogene as an early intervention option, the company seeks to alleviate the burden of recurrent disease and minimize the need for repetitive surgical interventions. This visionary approach aligns with CG Oncology’s overarching goal of establishing cretostimogene as a cornerstone oncolytic immunotherapy, poised to redefine the standard of care in bladder cancer treatment. With ongoing trials exploring combination therapies and building upon promising preliminary data, CG Oncology remains steadfast in its commitment to driving innovation and improving patient outcomes in the battle against cancer
Join us for the 2nd Annual Clinical Trials Festival Asia 2024 on the 20th-21st March 2024, proudly celebrating its successful second year as the region’s leading event for clinical trials and research leaders. Building upon the resounding success of our inaugural conference, we are thrilled to bring together industry experts once again to explore cutting-edge insights and advancements in the field. From protocol design to decentralized trials and effective trial management, this event offers valuable insights, networking opportunities, and collaboration to improve drug discovery and translation, ultimately benefiting patient outcomes. Asia’s potential in clinical research takes centre stage, providing a pivotal platform for discussing partnerships, regulations, patient engagement, and digital strategies. Engage, share, and differentiate in our vibrant discussions, contributing to collective efforts in addressing challenges and discovering transformative solutions. Save the date for Clinical Trials Festival Asia 2024 and stay tuned for further updates on our website. We eagerly anticipate your participation and the resounding success of this exceptional gathering. Find out more at https://imapac.com/events/clinical-trials-asia/
Source: https://www.clinicaltrialsarena.com/news/cg-oncology-bladder-cancer-trial/
